

? e au=pavliak, v?

Ref	Items	Index-term
E1	12	AU=PAVLIAK, V
E2	17	AU=PAVLIAK, V.
E3	0	AU=PAVLIAK, V?
E4	85	AU=PAVLIAK, VILLIAM
E5	1	AU=PAVLIAK, VILLAM
E6	21	AU=PAVLIAKOVA D
E7	11	AU=PAVLIAKOVA D.
E8	3	AU=PAVLIAKOVA DANKA
E9	6	AU=PAVLIAKOVA, D
E10	2	AU=PAVLIAKOVA, D.
E11	1	AU=PAVLIAKOVA, DANA
E12	6	AU=PAVLIAKOVA, DANKA
E13	9	AU=PAVLIASHVILI A T
E14	4	AU=PAVLIASHVILI G I
E15	2	AU=PAVLIASHVILI GI
E16	1	AU=PAVLIASHVILI I S
E17	2	AU=PAVLIASHVILI M K
E18	4	AU=PAVLIASHVILI N
E19	11	AU=PAVLIASHVILI N S
E20	2	AU=PAVLIASHVILI N.S.
E21	1	AU=PAVLIASHVILI NS
E22	1	AU=PAVLIASHVILI TI
E23	3	AU=PAVLIASHVILI V M
E24	3	AU=PAVLIASHVILI, G. I.
E25	1	AU=PAVLIASHVILI, M.K

Enter PAGE for more

? s e1-e5

	12	AU=PAVLIAK, V
	17	AU=PAVLIAK, V.
	0	AU=PAVLIAK, V?
	85	AU=PAVLIAK, VILLIAM
	1	AU=PAVLIAK, VILLAM
S1	115	S E1-E5

? s rd

S2 191199 S RD

? s s1

S3 115 S S1

? rd

>>>w: Duplicate detection is not supported for File 393.

Duplicate detection is not supported for File 391.

Records from unsupported files will be retained in the RD set.

S4 88 RD (UNIQUE ITEMS)

? s s4 and polysaccharide

	88	S4
	339274	POLYSACCHARIDE
S5	10	S S4 AND POLYSACCHARIDE

? rd

>>>w: Duplicate detection is not supported for File 393.

Duplicate detection is not supported for File 391.

Records from unsupported files will be retained in the RD set.

S6 10 RD (UNIQUE ITEMS)

? t s6/3,k/1-10

>>>w: KWIC option is not available in file(s): 399

6/3,k/1 (Item 1 from file: 24) Links

polysaccharide.txt
Fulltext available through: STIC Full Text Retrieval Options
CSA Life Sciences Abstracts
(c) 2008 CSA. All rights reserved.
0001664565 IP Accession No: 3977784
Capsular polysaccharide-protein conjugate vaccines

Sood, RK; Fattom, A; Pavliak, V; Naso, RB W.W. Karakawa Microbial Pathogenesis Lab.,
NABI, 12280 Wilkins Ave., Rockville, MD 20852, USA
Drug Discovery Today, v 1, n 9, p 381-387, 1996
Publication Date: 1996

Document Type: Journal Article
Record Type: Abstract
Language: English
Summary Language: English
ISSN: 1359-6446
File Segment: Industrial & Applied Microbiology Abstracts (Microbiology A); Medical
& Pharmaceutical Biotechnology Abstracts; Bacteriology Abstracts (Microbiology B)
Capsular polysaccharide-protein conjugate vaccines

Sood, RK; Fattom, A; Pavliak, V; Naso, RB

Abstract:
The conjugation of polysaccharides to carrier proteins generally enhances
polysaccharide immunogenicity and renders the immune response T-cell dependent. Such
enhancement of immunogenicity has made the use of conjugate vaccines possible in
populations that are otherwise unresponsive to polysaccharide vaccines. Here, the
authors discuss the value of capsular polysaccharide vaccines, their ability to
elicit protective immunity against infectious bacteria, the selection of appropriate
polysaccharides...

6/3,k/2 (Item 2 from file: 24) Links
Fulltext available through: STIC Full Text Retrieval Options
CSA Life Sciences Abstracts
(c) 2008 CSA. All rights reserved.
0001319212 IP Accession No: 3516276
Binding of the O-antigen of Shigella dysenteriae type 1 and 26 related synthetic
fragments to a monoclonal IgM antibody

Pavliak, V; Nashed, EM; Pozsgay, V; Kovac, P; Karpas, A; Chu, Chiayung; Schneerson,
R; Robbins, JB; Glaudemans, CPJ* NIDDKD/NIH, Bethesda, MD 20892, USA
Journal of Biological Chemistry, v 268, n 34, p 25797-25802, 1993
Addl. Source Info: Journal of Biological Chemistry [J. BIOL. CHEM.], vol. 268, no.
34, pp. 25797-25802, 1993
Publication Date: 1993

Document Type: Journal Article
Record Type: Abstract
Language: English
Summary Language: English
ISSN: 0021-9258
File Segment: Bacteriology Abstracts (Microbiology B)
Pavliak, V; Nashed, EM; Pozsgay, V; Kovac, P; Karpas, A; Chu, Chiayung; Schneerson,
R; Robbins, JB...

Abstract:
...monoclonal murine IgM for 26 fragments of, or related to, the structure of the
O-polysaccharide and of the IgM Fab for the intact O-specific bacterial
polysaccharide. Synthetic saccharides used were methyl glycosides to ensure an
anomerically defined pyranosyl ring conformation. Measurements using IgM Fab and the
intact O-specific polysaccharide show that the antibody can bind internal segments

polysaccharide.txt
on the antigen chain. The free energy...

6/3,K/3 (Item 3 from file: 24) Links
Fulltext available through: STIC Full Text Retrieval Options
CSA Life Sciences Abstracts
(c) 2008 CSA. All rights reserved.
0001060930 IP Accession No: 2580755
Immunochemical and structural analysis of the cell wall mannan as the basis of the
taxonomic reidentification of a yeast strain.
Pavliak, V; Kogan, G; Slavikova, E; Sandula, J; Masler, L Max-Planck-Inst.
Immunbiol., Stuebeweg 51, Postfach 1169, W-7800 Freiburg, FRG
Journal of Basic Microbiology, v 30, n 8, p 587-595, 1990
Addl. Source Info: Journal of Basic Microbiology [J. BASIC MICROBIOL.], vol. 30, no.
8, pp. 587-595, 1990
Publication Date: 1990

Document Type: Journal Article
Record Type: Abstract
Language: English
Summary Language: English
ISSN: 0233-111X
File Segment: Algology, Mycology & Protozoology Abstracts (Microbiology C)
Pavliak, V; Kogan, G; Slavikova, E; Sandula, J; Masler, L

Abstract:
...reidentified as *Hansenula anomala*. This work demonstrates that immunochemical
and structural investigations of cell-wall polysaccharide components can serve as a
basis for taxonomic identification of yeast strains.

6/3,K/4 (Item 1 from file: 393) Links
Beilstein Database - Abstracts
(c) 2008 Beilstein GmbH. All rights reserved.
Beilstein Abstract Id: 6005712
Title: Structural elucidation of the capsular polysaccharide of *Bacteroides fragilis*
strain 23745M1
Document Type: Journal Record Type: Abstract
Author: Pavliak, Viliam; Uhrin, Dusan; Brisson, Jean-Robert; Tzianabos, Arthur O.;
Kasper, Dennis L.; Jennings, Harold J.
Citation: Carbohydr. Res. (1995) Series: 275-2, 333-342 CODEN: CRBRAT Language:
English
Abstract Language: English
Title: Structural elucidation of the capsular polysaccharide of *Bacteroides fragilis*
strain 23745M1
Document Type:
Author: Pavliak, Viliam; Uhrin, Dusan; Brisson, Jean-Robert; Tzianabos, Arthur O.;
Kasper, Dennis L.; Jennings, Harold J.
Patent Assignee:
Abstract: ... of which could not be accomplished. The mouse-passaged strain
(23745M1), however, yielded a preponderant polysaccharide which was isolated and
purified. Using mainly high resolution NMR spectroscopy, the structure of the
polysaccharide was elucidated and it is composed of the following repeating unit:
(formula) where alpha -L... is 3,6 dideoxy-4-C-(L-glycero-4'-hydroxyethyl)-
alpha -D-xylo-hexopyranoside. Keywords: Polysaccharide; *Bacteroides fragilis*; NMR
Abstract Language:

6/3,K/5 (Item 1 from file: 399) Links
CA SEARCH(R)

polysaccharide.txt
(c) 2008 American Chemical Society. All rights reserved.

141294673 CA: 141(18)294673p PATENT
Capsular polysaccharide-staphylococcal surface adhesin carrier protein conjugates as vaccines for immunization against nosocomial infections
Inventor (Author): Pavliak, Viliam; Baker, Steven Morris; Pillai, Subramonia Padmanaba
Location: USA
Assignee: Wyeth Holdings Corporation; Wyeth Corp.
Patent: PCT International ; WO 200480490 A2 Date: 20040923
Application: WO 2004US6661 (20040304) *US PV452728 (20030307)
Pages: 81 pp.
CODEN: PIXXD2
Language: English
Patent Classifications:
Class: A61K-047/48A; C07K-016/12B; A61K-039/385B
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW
Designated Regional: BW; GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3,K/6 (Item 2 from file: 399) Links
Fulltext available through: STIC Full Text Retrieval Options
CA SEARCH(R)
(c) 2008 American Chemical Society. All rights reserved.

123280458 CA: 123(21)280458p JOURNAL
Structural elucidation of the capsular polysaccharide of *Bacteroides fragilis* strain 23745M1
Author: Pavliak, Viliam; Uhrin, Dusan; Brisson, Jean-Robert; Tzianabos, Arthur O.; Kasper, Dennis L.; Jennings, Harold J.
Location: Institute Biological Sciences, National Research Council Canada, Ottawa, ON, Can., K1A 0R6
Journal: Carbohydr. Res.
Date: 1995
Volume: 275 Number: 2 Pages: 333-41
CODEN: CRBRAT
ISSN: 0008-6215
Language: English

6/3,K/7 (Item 3 from file: 399) Links
Fulltext available through: STIC Full Text Retrieval Options
CA SEARCH(R)
(c) 2008 American Chemical Society. All rights reserved.

117111922 CA: 117(11)111922f JOURNAL
Synthesis of ligands related to the O-specific antigen *Shigella dysenteriae* type 1. Part 2. Stereoselective syntheses of a di-, tri-, and tetrasaccharide fragment of *Shigella dysenteriae* type-1 O-antigen using 3,4,6-tri-O-acetyl-2-azido-2-deoxy- α -D-glucopyranosyl chloride as a glycosyl donor
Author: Pavliak, Viliam; Kovac, Pavol; Glaudemans, Cornelis P. J.
Location: Natl. Inst. Health, Bethesda, MD, 20892, USA
Journal: Carbohydr. Res.
Date: 1992
Volume: 229 Number: 1 Pages: 103-16

polysaccharide.txt

CODEN: CRBRAT
ISSN: 0008-6215
Language: English

6/3,K/8 (Item 1 from file: 391) Links
Beilstein Database - Reactions
(C) 2008 Beilstein GmbH. All rights reserved.
Reaction Id: 3880636

Reactants

BN=96634 O 1, O 3, O 4, O 6 -Tetraacetyl- beta -D-mannopyranose
BN=1813600 trifluoro-methanesulfonic acid anhydride

Products

BN=4341413 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethylsulfonyl- beta

-D-mannopyranose

No. of Reaction Details: 5

No. of References: 6

References

...John B. ; Schneerson, Rachel Synthesis of a Tetrasaccharide Building Block of the O-Specific Polysaccharide of Shigella dysenteriae Type 1 TETRAB ; Tetrahedron ; 48-47(1992)10249-10264;

5... ..THIO-D-GLUCOPYRANOSE (THIOSOPHOROSE) CRBRAT ; Carbohydr.Res. ; 128 (1984)291-296;

6, 5540312 Pavliak, Viliam ; Kovac, Pavol A short synthesis of 1,3,4,6-tetra-O-acetyl...

6/3,K/9 (Item 2 from file: 391) Links
Beilstein Database - Reactions
(C) 2008 Beilstein GmbH. All rights reserved.
Reaction Id: 3361579

Reactants

BN=3629273 Methyl 2,4-Di-O-benzoyl- alpha -L-rhamnopyranoside
BN=605440 bromoacetyl bromide

Products

BN=5461795 methyl 2,4-di-O-benzoyl-3-O-bromoacetyl- alpha -L-rhamnopyranoside

No. of Reaction Details: 2

No. of References: 2

References

1, 5663069 Pavliak, Viliam ; Kovac, Pavol ; Glaudemans, Cornelis P. J. Stereoselective syntheses of a di-, tri... ..Pozsgay, Vince ; Pannell, Lewis Convergent synthesis of an octasaccharide fragment of the O-specific polysaccharide of Shigella dysenteriae type 1 CRBRAT ; Carbohydr.Res. ; 258 (1994)105-122;

6/3,K/10 (Item 3 from file: 391) Links
Beilstein Database - Reactions
(C) 2008 Beilstein GmbH. All rights reserved.
Reaction Id: 2518469

Reactants

BN=4341413 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethylsulfonyl- beta

-D-mannopyranose

Products

BN=4337930 1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy- beta -D-glucopyranose

No. of Reaction Details: 4

No. of References: 4

References

...John B. ; Schneerson, Rachel Synthesis of a Tetrasaccharide Building Block of the O-Specific Polysaccharide of Shigella dysenteriae Type 1 TETRAB ; Tetrahedron ; 48-47(1992)10249-10264;

4, 5540312 Pavliak, Viliam ; Kovac, Pavol A short synthesis of

polysaccharide.txt

1,3,4,6-tetra-0-acetyl...

? e au=baker, steven?

Ref	Items	Index-term
E1	0	AU=BAKER, STEVEN?
E2	64	AU=BAKER, STEWART
E3	1	AU=BAKER, STEWART ADDISON
E4	117	AU=BAKER, STEWART J.
E5	2	AU=BAKER, STEWART JAMES
E6	1	AU=BAKER, STFANIE H
E7	2	AU=BAKER, STOKES S
E8	3	AU=BAKER, STOKES S.
E9	2	AU=BAKER, STOKES SIDNEY
E10	7	AU=BAKER, STUART
E11	2	AU=BAKER, STUART A
E12	7	AU=BAKER, STUART A.
E13	1	AU=BAKER, STUART EDDY
E14	11	AU=BAKER, STUART G
E15	13	AU=BAKER, STUART G.
E16	1	AU=BAKER, STUART J.
E17	1	AU=BAKER, STUART JOHN
E18	17	AU=BAKER, STUART N
E19	1	AU=BAKER, STUART N.
E20	1	AU=BAKER, STUART ROY
E21	3	AU=BAKER, SU
E22	8	AU=BAKER, SUE
E23	1	AU=BAKER, SUE A
E24	1	AU=BAKER, SUE A.
E25	1	AU=BAKER, SUE HELTON

Enter PAGE for more

? e au=pillai, subramonia?

Ref	Items	Index-term
E1	1	AU=PILLAI, SUBRAMONIA PADMANABA
E2	1	AU=PILLAI, SUBRAMONIA PADMANABHA
E3	0	AU=PILLAI, SUBRAMONIA?
E4	1	AU=PILLAI, SUJATHA
E5	1	AU=PILLAI, SUKUMARAN
E6	2	AU=PILLAI, SUMA
E7	1	AU=PILLAI, SUMESH SOFIN RAMAKRISHNA PILLAI GOPALA
E8	1	AU=PILLAI, SUMITRA ASHOK
E9	1	AU=PILLAI, SUNIL K.
E10	2	AU=PILLAI, SUNIL KUMAR C.
E11	1	AU=PILLAI, SUNILKUMAR BHADRAMMA KOCHUNARAYANA
E12	5	AU=PILLAI, SUNILKUMAR C.
E13	2	AU=PILLAI, SUPRIYA
E14	1	AU=PILLAI, SURECH C.
E15	14	AU=PILLAI, SURESH
E16	4	AU=PILLAI, SURESH B.
E17	2	AU=PILLAI, SURESH BISWANATH
E18	4	AU=PILLAI, SURESH C
E19	31	AU=PILLAI, SURESH C.
E20	49	AU=PILLAI, SURESH D
E21	80	AU=PILLAI, SURESH D.
E22	2	AU=PILLAI, SURESH D*
E23	2	AU=PILLAI, SURESH DIVAKARAN
E24	2	AU=PILLAI, SURESH KUMAR
E25	1	AU=PILLAI, SURESH KUMAR S.

Enter PAGE for more

? s e1-e2

1	AU=PILLAI, SUBRAMONIA PADMANABA
1	AU=PILLAI, SUBRAMONIA PADMANABHA

polysaccharide.txt

S1 2 S E1-E2

? rd

>>>W: Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S2 2 RD (UNIQUE ITEMS)

? e au=patti, joseph?

Ref	Items	Index-term
E1	25	AU=PATTI, JOSEPH M
E2	66	AU=PATTI, JOSEPH M.
E3	0	AU=PATTI, JOSEPH?
E4	1	AU=PATTI, K.
E5	2	AU=PATTI, K. J.
E6	1	AU=PATTI, KENNETH
E7	1	AU=PATTI, KISER
E8	1	AU=PATTI, L
E9	48	AU=PATTI, L.
E10	1	AU=PATTI, L. M.
E11	1	AU=PATTI, L.M.
E12	1	AU=PATTI, LARVSSA
E13	1	AU=PATTI, LARYSSA
E14	6	AU=PATTI, LAURA
E15	9	AU=PATTI, LIDIA
E16	3	AU=PATTI, LISA
E17	3	AU=PATTI, LISA M.
E18	1	AU=PATTI, LMILLS
E19	4	AU=PATTI, M
E20	6	AU=PATTI, M.
E21	19	AU=PATTI, M. E.
E22	29	AU=PATTI, M. G.
E23	11	AU=PATTI, M. J.
E24	1	AU=PATTI, M. K.
E25	5	AU=PATTI, M.-E.

Enter PAGE for more

? s e1-e2

	25	AU=PATTI, JOSEPH M
	66	AU=PATTI, JOSEPH M.
S3	91	S E1-E2

? rd

>>>W: Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S4 66 RD (UNIQUE ITEMS)

? s s4 and polysaccharide

	66	S4
	339274	POLYSACCHARIDE
S5	0	S S4 AND POLYSACCHARIDE

? s s4

S6	66	S S4
----	----	------

? e au=bradley, prater?

Ref	Items	Index-term
E1	8	AU=BRADLEY, PP
E2	1	AU=BRADLEY, PR
E3	0	AU=BRADLEY, PRATER?
E4	8	AU=BRADLEY, PRUDENCE
E5	2	AU=BRADLEY, PRUDENCE K

polysaccharide.txt

```

E6      85 AU=BRADLEY, PRUDENCE K.
E7      2 AU=BRADLEY, PRUDENCE KATHERINE
E8      3 AU=BRADLEY, PS
E9      2 AU=BRADLEY, PV
E10     18 AU=BRADLEY, PW
E11     2 AU=BRADLEY, Q.
E12     1 AU=BRADLEY, Q.M.
E13     1 AU=BRADLEY, QUETZALCOATL
E14     76 AU=BRADLEY, R
E15     2 AU=BRADLEY, R (ED)
E16     1 AU=BRADLEY, R D
E17     2 AU=BRADLEY, R F
E18     1 AU=BRADLEY, R M
E19     1 AU=BRADLEY, R MARK
E20     1 AU=BRADLEY, R S
E21     525 AU=BRADLEY, R.
E22     2 AU=BRADLEY, R. A
E23     146 AU=BRADLEY, R. A.
E24     2 AU=BRADLEY, R. ANDREW
E25     10 AU=BRADLEY, R. B.
Enter PAGE for more

```

? e au=bradley, p?

```

Ref  Items  Index-term
E1      5 AU=BRADLEY, P.S.
E2      7 AU=BRADLEY, P.W.
E3      0 AU=BRADLEY, P?
E4      7 AU=BRADLEY, PA
E5      3 AU=BRADLEY, PAIGE
E6      1 AU=BRADLEY, PAMELA
E7      1 AU=BRADLEY, PAMELA ANNE
E8      1 AU=BRADLEY, PAMELA D.
E9      1 AU=BRADLEY, PAMELA F.
E10     2 AU=BRADLEY, PAMELA F.
E11     26 AU=BRADLEY, PAMELA J.
E12     1 AU=BRADLEY, PAMELA JEAN
E13     4 AU=BRADLEY, PAMELA L
E14     4 AU=BRADLEY, PAMELA L.
E15     2 AU=BRADLEY, PAMELA LYNN
E16     1 AU=BRADLEY, PAMELA NEWELL
E17     1 AU=BRADLEY, PATRIC W.
E18     1 AU=BRADLEY, PATRICE
E19     12 AU=BRADLEY, PATRICIA
E20     1 AU=BRADLEY, PATRICIA A.
E21     1 AU=BRADLEY, PATRICIA ANN
E22     1 AU=BRADLEY, PATRICIA ANN HAYES
E23     1 AU=BRADLEY, PATRICIA ANNE LANKFORD
E24     2 AU=BRADLEY, PATRICIA E
E25     5 AU=BRADLEY, PATRICIA E.
Enter PAGE for more

```

? page

```

Ref  Items  Index-term
E26     3 AU=BRADLEY, PATRICIA J.
E27     1 AU=BRADLEY, PATRICIA JANE
E28     1 AU=BRADLEY, PATRICIA JEAN
E29     1 AU=BRADLEY, PATRICIA K.
E30     2 AU=BRADLEY, PATRICIA KAREN
E31     9 AU=BRADLEY, PATRICIA M
E32     14 AU=BRADLEY, PATRICIA M.
E33     2 AU=BRADLEY, PATRICIA MARIE GEISE
E34     15 AU=BRADLEY, PATRICK
E35     4 AU=BRADLEY, PATRICK B.

```


polysaccharide.txt

E36	1	AU=BRADLEY, PATRICK DAVID
E37	1	AU=BRADLEY, PATRICK ERIK
E38	6	AU=BRADLEY, PATRICK J
E39	7	AU=BRADLEY, PATRICK J.
E40	1	AU=BRADLEY, PATRICK JOSEPH
E41	12	AU=BRADLEY, PATRICK W
E42	32	AU=BRADLEY, PATRICK W.
E43	1	AU=BRADLEY, PATRICK WALTON
E44	1	AU=BRADLEY, PATRICK J
E45	1	AU=BRADLEY, PATTI
E46	44	AU=BRADLEY, PAUL
E47	188	AU=BRADLEY, PAUL A.
E48	3	AU=BRADLEY, PAUL ANDREW
E49	7	AU=BRADLEY, PAUL ANTHONY
E50	1	AU=BRADLEY, PAUL ARTHUR

Enter PAGE for more

? page

Ref	Items	Index-term
E1	1	AU=BRADLEY, PAUL ARTHUR
E2	1	AU=BRADLEY, PAUL D
E3	16	AU=BRADLEY, PAUL D.
E4	2	AU=BRADLEY, PAUL DOUGLAS
E5	9	AU=BRADLEY, PAUL G.
E6	1	AU=BRADLEY, PAUL GRANT
E7	2	AU=BRADLEY, PAUL GREGG
E8	1	AU=BRADLEY, PAUL H
E9	1	AU=BRADLEY, PAUL JONATHAN
E10	100	AU=BRADLEY, PAUL M
E11	134	AU=BRADLEY, PAUL M.
E12	1	AU=BRADLEY, PAUL MARTIN
E13	1	AU=BRADLEY, PAUL MICAH
E14	2	AU=BRADLEY, PAUL MICHAEL
E15	1	AU=BRADLEY, PAUL N.
E16	77	AU=BRADLEY, PAUL R.
E17	4	AU=BRADLEY, PAUL S.
E18	2	AU=BRADLEY, PAUL S.
E19	1	AU=BRADLEY, PAUL STEPHEN
E20	1	AU=BRADLEY, PAULA WYNELL
E21	1	AU=BRADLEY, PAULETTE NANNOS
E22	3	AU=BRADLEY, PAULEY R.
E23	6	AU=BRADLEY, PB
E24	4	AU=BRADLEY, PD
E25	2	AU=BRADLEY, PE

Enter PAGE for more

? page

Ref	Items	Index-term
E26	1	AU=BRADLEY, PEARL GARRETT
E27	1	AU=BRADLEY, PEARLE ELIZABETH QUINN
E28	1	AU=BRADLEY, PEGGY ELLEN
E29	1	AU=BRADLEY, PEGGY M
E30	145	AU=BRADLEY, PERRY
E31	23	AU=BRADLEY, PETER
E32	1	AU=BRADLEY, PETER A
E33	2	AU=BRADLEY, PETER A.
E34	5	AU=BRADLEY, PETER D.
E35	1	AU=BRADLEY, PETER DOUGLAS
E36	2	AU=BRADLEY, PETER G.
E37	12	AU=BRADLEY, PETER J
E38	34	AU=BRADLEY, PETER J.
E39	1	AU=BRADLEY, PETER JAMES
E40	4	AU=BRADLEY, PETER JOHN

polysaccharide.txt

E41 1 AU=BRADLEY, PETER K.
 E42 2 AU=BRADLEY, PETER M.
 E43 7 AU=BRADLEY, PETER M.
 E44 1 AU=BRADLEY, PETER M. J.
 E45 1 AU=BRADLEY, PETER M. J.
 E46 2 AU=BRADLEY, PETER MICHAEL
 E47 2 AU=BRADLEY, PETER P.
 E48 3 AU=BRADLEY, PETER V.
 E49 2 AU=BRADLEY, PETER V.
 E50 1 AU=BRADLEY, PETER VINCE
 Enter PAGE for more

? page

Ref	page	Items	Index-term
E1	1	AU=BRADLEY,	PETER VINCE
E2	3	AU=BRADLEY,	PG
E3	2	AU=BRADLEY,	PH
E4	20	AU=BRADLEY,	PHIL
E5	20	AU=BRADLEY,	PHILIP
E6	1	AU=BRADLEY,	PHILIP AUSTIN
E7	8	AU=BRADLEY,	PHILIP B (ED)
E8	20	AU=BRADLEY,	PHILIP B.
E9	1	AU=BRADLEY,	PHILIP DURGAN, JR.
E10	1	AU=BRADLEY,	PHILIP G.
E11	2	AU=BRADLEY,	PHILIP H.
E12	1	AU=BRADLEY,	PHILIP L.
E13	3	AU=BRADLEY,	PHILIP M.
E14	1	AU=BRADLEY,	PHILIP T.
E15	2	AU=BRADLEY,	PHILLIP
E16	2	AU=BRADLEY,	PHILLIP J
E17	1	AU=BRADLEY,	PHILLIP K.
E18	1	AU=BRADLEY,	PICRO J.
E19	1	AU=BRADLEY,	PIERO J
E20	2	AU=BRADLEY,	PIERO J.
E21	23	AU=BRADLEY,	PJ
E22	2	AU=BRADLEY,	PL
E23	236	AU=BRADLEY,	PM
E24	4	AU=BRADLEY,	PM*
E25	8	AU=BRADLEY,	PN
Enter PAGE for more			

? page

Ref	page	Items	Index-term
E26	8	AU=BRADLEY,	PP
E27	1	AU=BRADLEY,	PR
E28	8	AU=BRADLEY,	PRUDENCE
E29	2	AU=BRADLEY,	PRUDENCE K
E30	85	AU=BRADLEY,	PRUDENCE K.
E31	2	AU=BRADLEY,	PRUDENCE KATHERINE
E32	3	AU=BRADLEY,	PS
E33	2	AU=BRADLEY,	PV
E34	18	AU=BRADLEY,	PW
E35	2	AU=BRADLEY,	Q.
E36	1	AU=BRADLEY,	Q.M.
E37	1	AU=BRADLEY,	QUETZALCOATL
E38	76	AU=BRADLEY,	R
E39	2	AU=BRADLEY,	R (ED)
E40	1	AU=BRADLEY,	R D
E41	2	AU=BRADLEY,	R F
E42	1	AU=BRADLEY,	R M
E43	1	AU=BRADLEY,	R MARK
E44	1	AU=BRADLEY,	R S
E45	525	AU=BRADLEY,	R.

polysaccharide.txt

```

E46      2 AU=BRADLEY, R. A
E47     146 AU=BRADLEY, R. A.
E48      2 AU=BRADLEY, R. ANDREW
E49     10 AU=BRADLEY, R. B.
E50     17 AU=BRADLEY, R. C.
Enter PAGE for more

```

? e au=bradley, prater

Ref	Items	Index-term
E1	8	AU=BRADLEY, PP
E2	1	AU=BRADLEY, PR
E3	0	AU=BRADLEY, PRATER
E4	8	AU=BRADLEY, PRUDENCE
E5	2	AU=BRADLEY, PRUDENCE K
E6	85	AU=BRADLEY, PRUDENCE K.
E7	2	AU=BRADLEY, PRUDENCE KATHERINE
E8	3	AU=BRADLEY, PS
E9	2	AU=BRADLEY, PV
E10	18	AU=BRADLEY, PW
E11	2	AU=BRADLEY, Q.
E12	1	AU=BRADLEY, Q.M.
E13	1	AU=BRADLEY, QUETZALCOATL
E14	76	AU=BRADLEY, R
E15	2	AU=BRADLEY, R (ED)
E16	1	AU=BRADLEY, R D
E17	2	AU=BRADLEY, R F
E18	1	AU=BRADLEY, R M
E19	1	AU=BRADLEY, R MARK
E20	1	AU=BRADLEY, R S
E21	525	AU=BRADLEY, R.
E22	2	AU=BRADLEY, R. A
E23	146	AU=BRADLEY, R. A.
E24	2	AU=BRADLEY, R. ANDREW
E25	10	AU=BRADLEY, R. B.

Enter PAGE for more

? d s

Set	Items	Description
S1	2	S E1-E2
S2	2	RD (unique items)
S3	91	S E1-E2
S4	66	RD (unique items)
S5	0	S S4 AND POLYSACCHARIDE
S6	66	S S4

? s (polysaccharide and (carrier(w)protein))

Processing
Processing
Processing
Processing

	339274	POLYSACCHARIDE
	1313075	CARRIER
	16905514	PROTEIN
	89519	CARRIER(w)PROTEIN
S7	1633	S (POLYSACCHARIDE AND (CARRIER(w)PROTEIN))

?

? s s7 and (adhesin or adhesion)

	1633	S7
	36651	ADHESIN
	1404771	ADHESION
S8	20	S S7 AND (ADHESIN OR ADHESION)

polysaccharide.txt

?

? rd

>>>W: Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S9 16 RD (UNIQUE ITEMS)

? t s9/3,k/1-16

>>>W: KWIC option is not available in file(s): 399
9/3,k/1 (Item 1 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

(C) 2008 The Thomson Corporation. All rights reserved.
17578626 Biosis No.: 200300533523
Synthesis and immunological properties of the staphylococcal
poly-N-acetylglucosamine (PNAG) and deacetylated-poly-N-acetylglucosamine (dPNAG)
surface polysaccharides conjugated to diphtheria toxoid.

Author: Maira-Litran T (Reprint); Kropec A (Reprint); Pier G B (Reprint)
Author Address: Channing Laboratory, Harvard Medical School, Boston, MA, USA**USA
Journal: Abstracts of the General Meeting of the American Society for Microbiology
103 p E-121 2003 2003
Medium: cd-rom
Conference/Meeting: 103rd American Society for Microbiology General Meeting
Washington, DC, USA May 18-22, 2003; 20030518
Sponsor: American Society for Microbiology
ISSN: 1060-2011_(ISSN print)
Document Type: Meeting; Meeting Abstract
Record Type: Abstract
Language: English

Abstract: Background: The intercellular adhesin locus (ica) of *S. aureus* and *S. epidermidis* encodes proteins that synthesize the capsular polysaccharide/adhesin (PS/A) and that this antigen serves as target for protective immunity. PNAG is the... ..and a deacetylated form of this surface antigen (15-20% substitution) were conjugated to the carrier protein diphtheria toxoid (DT). Mice were immunized with 0.15, 0.75 and 1.5 mg... ..bled weekly for one month. Control mice were immunized with a mixture of the unconjugated polysaccharide and protein in the same ratio. Antibody responses were measured by ELISA and opsonophagocytic killing...

9/3,K/2 (Item 1 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci

(C) 2008 The Thomson Corp. All rights reserved.
18600645 Genuine Article#: 381HA No. References: 61
Solid-state NMR studies of bacterial lipoteichoic acid adsorption on different surfaces

Author: Wickham JR; Rice CV (REPRINT)
Corporate Source: Univ Oklahoma, Dept Chem & Biochem, 620 Parrington Oval, Room 208/Norman/OK/73019 (REPRINT); Univ Oklahoma, Dept Chem & Biochem, Norman/OK/73019
Journal: SOLID STATE NUCLEAR MAGNETIC RESONANCE, 2008, v 34, N3 (OCT), P 154-161
ISSN: 0926-2040 Publication date: 20081000
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: Teichoic acids are important to bacteria for surface adhesion, metal ion coordination, and other biological processes crucial to bacterial survival. In particular, the surface adhesion of teichoic acids plays a crucial role in the formation of Gram-positive biofilms. Biofilmsof various chronic infections. Biofilm formation is essentially a four-step process beginning with the adhesion of

polysaccharide.txt
bacteria to a surface, followed by the excretion of an extracellular polymeric substance (slime... ..through bacterial release. Currently, there is very little molecular level information available for the initial adhesion of bacteria to solid surfaces. Solid-state NMR is ideally suited for the study of these samples, thus we use (31)p solid-state NMR experiments to study the initial adhesion of lipoteichoic acid (LTA) to various surfaces. P-31 CP-MAS spectra and T-1p... ..we suggest that the alanine and glucosamine groups interact with the surface. However, during simultaneous adhesion to TiO2 and PGN, the glucosamine groups bind to the PGN while the alanine groups...
Identifiers-- ...POLYSACCHARIDE INTERCELLULAR ADHESIN; FORMING STAPHYLOCOCCUS-EPIDERMIDIS; ALANYL CARRIER PROTEIN; TEICHOIC-ACIDS; STREPTOCOCCUS-PNEUMONIAE; BIOFILM FORMATION; MOLECULAR-STRUCTURE; POTENT STIMULUS; PHASE VARIATION; HOST DEFENSES

9/3,K/3 (Item 2 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
14375190 Genuine Article#: 967JN No. References: 54
Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal
poly-N-acetyl-beta-(1-6)-glucosamine

Author: Maira-Litran T (REPRINT) ; Kropec A; Goldmann DA; Pier GB
Corporate Source: Harvard Univ,Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab,181 Longwood Ave/Boston//MA/02115 (REPRINT); Harvard Univ,Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab,Boston//MA/02115; Harvard Univ,Sch Med, Childrens Hosp, Dept Med,Div Infect Dis,Boston//MA/02115 (tmaira@rics.bwh.harvard.edu)
Journal: INFECTION AND IMMUNITY , 2005 , v 73 , N10 (OCT) , P 6752-6762
ISSN: 0019-9567 Publication date: 20051000
Publisher: AMER SOC MICROBIOLOGY , 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: Staphylococcus aureus and Staphylococcus epidermidis both synthesize the surface polysaccharide poly-N-acetyl-beta-(1-6)-glucosamine (PNAG), which is produced in vitro with a... ..PNAG and a deacetylated form of the antigen (dPNAG; 15% acetylation) were conjugated to the carrier protein diphtheria toxoid (DT) and used to immunize animals. Mice responded in a dose-dependent fashion... ..dPNAG elicit antibodies that mediated opsonic killing and protected against S. aureus infection, including capsular polysaccharide types 5 and 8 and an untypable strain.
Identifiers-- ...CAPSULAR POLYSACCHARIDE ADHESIN; COAGULASE-NEGATIVE STAPHYLOCOCCI; CATHETER-ASSOCIATED INFECTION; METHICILLIN-RESISTANT; INTERCELLULAR ADHESIN; SURFACE POLYSACCHARIDE; MONOCLONAL-ANTIBODIES; BIOFILM FORMATION; RABBIT MODEL; ICA LOCUS

9/3,K/4 (Item 1 from file: 45) Links
EMCare
(c) 2008 Elsevier B.V. All rights reserved.
0004168992 EMCARE No: 35614584
Novel sucrose-dependent adhesion co-factors in Streptococcus mutans.

Tao L.; Tanzer J.M.
Department of Oral Biology, College of Dentistry, University of Illinois at Chicago, 60612, USA.
CORRESP. AUTHOR/AFFIL: Tao L.: Department of Oral Biology, College of Dentistry, University of Illinois at Chicago, 60612, USA.
CORRESP. AUTHOR EMAIL: ltiao@uic.edu

Journal of dental research (J. Dent. Res.) (United States) July 1, 2002 , 81/7 (505-510)
ISSN: 0022-0345
DOCUMENT TYPE: Journal ; Article RECORD TYPE: Abstract
LANGUAGE: English

polysaccharide.txt
Novel sucrose-dependent adhesion co-factors in Streptococcus mutans.

Streptococcus mutans glucosyltransferases form extracellular glucans from sucrose to promote adhesion to the teeth. We tested whether additional factors are involved in *S. mutans* sucrose-dependent adhesion. By screening a pVA891-insertion mutant library of *S. mutans* LT11, we isolated four clones deficient in adhesion to glass in the presence of sucrose, but normal in glucosyltransferase activities. The genetic loci... to the wild type. Therefore, these four factors may contribute to *S. mutans* sucrose-dependent adhesion.

DESCRIPTORS:

* adhesion; *Streptococcus mutans; *sucrose
ABC transporter; adenosine triphosphate; analysis of variance; antibiotic resistance; ascorbic acid; ascorbic acid metabolism; bacterial polysaccharide; bacterial protein; bacterium adherence; bacterium transformation; biosynthesis; carrier protein; cell clone; chromosome map; clone; effusion; enzymology; erythromycin; gene locus; genetics; glass; glucan; glucosyltransferase; glycerol...
TERMS (UNCONTROLLED):

9/3,K/5 (Item 2 from file: 45) Links

EMCare

(c) 2008 Elsevier B.V. All rights reserved.

0004168104 EMCARE No: 35607797

Attenuation of glucan-binding protein C reduces the cariogenicity of *Streptococcus mutans*: analysis of strains isolated from human blood.

Nakano K.; Matsumura M.; Kawaguchi M.; Fujiwara T.; Sobue S.; Nakagawa I.; Hamada S.; Ooshima T.

Department of Pedodontics, Osaka University Graduate School of Dentistry, 1-8 Yamada-oka, Suita, Osaka 565-0871, Japan.

CORRESP. AUTHOR/AFFIL: Nakano K.: Department of Pedodontics, Osaka University Graduate School of Dentistry, 1-8 Yamada-oka, Suita, Osaka 565-0871, Japan.

Journal of dental research (J. Dent. Res.) (United States) June 1, 2002 , 81/6 (376-379)

ISSN: 0022-0345

DOCUMENT TYPE: Journal ; Article RECORD TYPE: Abstract

LANGUAGE: English

...relatively low homology with MT8148, a reference oral isolate strain, and lacks the serotype-specific polysaccharide antigen, suggesting that other cell-surface structures correlate with cariogenicity. We compared cariogenicity of TW871... showed significantly lower cariogenicity than MT8148 or TW964 and expressed significantly lower sucrose-independent cellular adhesion to saliva-coated hydroxyapatite and dextran-binding activity than strain MT8148. Strains TW871 and TW964...

DESCRIPTORS:

*
adhesion; analysis of variance; antigen; bacteremia; bacterial endocarditis; bacterial protein; bacterium adherence; binding affinity; carrier protein; cell surface; child; classification; dental caries; dextran; DNA; DNA sequence; gene; genetic variability; genetics; germfree animal; human; hydroxyapatite; immunology; metabolism; microbiology; molecular genetics; pathogenicity; physiology; polysaccharide; rat; rat strain; saliva; sequence analysis; serotype ; site directed mutagenesis; Southern blotting; species difference; sucrose ...
TERMS (UNCONTROLLED):

9/3,K/6 (Item 1 from file: 72) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

Page 14

polysaccharide.txt

0082727018 EMBASE No: 2008529839

Characterization of the *Caulobacter crescentus* holdfast polysaccharide biosynthesis pathway reveals significant redundancy in the initiating glycosyltransferase and polymerase steps

Toh E.; Kurtz Jr. H.D.; Brun Y.V.

Department of Biology, Indiana University, Bloomington, IN 47405-3700, United States

Author email: ybrun@indiana.edu

Corresp. Author/Affil: Brun Y. V.: Department of Biology, Indiana University, Bloomington, IN 47405-3700, United States

Corresp. Author Email: ybrun@indiana.edu

Journal of Bacteriology (J. Bacteriol.) (United States) November 1, 2008 , 190/21 (7219-7231)

CODEN: JOBAA ISSN: 0021-9193

Item Identifier (DOI): 10.1128/JB.01003-08

URL: <http://jb.asm.org/cgi/reprint/190/21/7219>

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 69

Characterization of the *Caulobacter crescentus* holdfast polysaccharide biosynthesis pathway reveals significant redundancy in the initiating glycosyltransferase and polymerase steps

Caulobacter crescentus cells adhere to surfaces by using an extremely strong polar adhesion called the holdfast. The polysaccharide component of the holdfast is comprised in part of oligomers of N-acetylglucosamine. The genes involved in the export of the holdfast polysaccharide and the anchoring of the holdfast to the cell were previously discovered. In this study, we identified a cluster of polysaccharide biosynthesis genes (*hfsEFGH*) directly adjacent to the holdfast polysaccharide export genes. Sequence analysis indicated that these genes are involved in the biosynthesis of the minimum repeat unit of the holdfast polysaccharide. *HfsE* is predicted to be a UDP-sugar lipid-carrier transferase, the glycosyltransferase that catalyzes the first step in polysaccharide biosynthesis. *HfsF* is predicted to be a flippase, *HfsG* is a glycosyltransferase, and *HfsH* is similar to a polysaccharide (chitin) deacetylase. In-frame *hfsG* and *hfsH* deletion mutants resulted in severe deficiencies both in surface adhesion and in binding to the holdfast-specific lectin wheat germ agglutinin. In contrast, *hfsE* and *hfsF* mutants exhibited nearly wild-type levels of adhesion and holdfast synthesis. We identified three paralogs to *hfsE*, two of which are redundant to... ..holdfast synthesis. We also identified a redundant paralog to the *hfsC* gene, encoding the putative polysaccharide polymerase, and present evidence that the *hfsE* and *hfsC* paralogs, together with the *hfs* genes...

Drug Descriptors:

* glycosyltransferase--endogenous compound--ec; *polysaccharide --endogenous compound--ec

carrier protein--endogenous compound--ec; chitin--endogenous compound--ec; mutant protein--endogenous compound--ec; unclassified drug; uridine...

Medical Descriptors:

article; bacterial gene; carbohydrate synthesis; cell adhesion; cell surface; controlled study; gene cluster; gene deletion; gene identification ; nonhuman; nucleotide sequence; priority journal...

Orig. Descriptors:

CAS Registry Number: 80700-39-6 (carrier protein); 1398-61-4 (chitin); 9033-07-2 (glycosyltransferase)

SECTION HEADINGS:

9/3,K/7 (Item 2 from file: 72) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

Page 15

polysaccharide.txt

0082188694 EMBASE No: 2007602508

Meningococcal disease: A review on available vaccines and vaccines in development

Broker M.; Fantoni S.
Novartis Vaccines, Marburg, Germany; Novartis Vaccines, Emil von Behring-Str 76,
35041 Marburg, Germany
Author email: Michael.Broeker@Novartis.com
Corresp. Author/Affil: Broker M.: Novartis Vaccines, Emil von Behring-Str 76, 35041
Marburg, Germany
Corresp. Author Email: Michael.Broeker@Novartis.com

Minerva Medica (Minerva Med.) (Italy) October 1, 2007 , 98/5 (575-589)
CODEN: MIMEA ISSN: 0026-4806
Document Type: Journal ; Review Record Type: Abstract
Language: English Summary language: English; Italian
Number of References: 54

...conjugate vaccines have since been developed, which offer solid advantages over the currently licensed plain polysaccharide vaccines. Tetravalent serogroup A, C, Y and W135 meningococcal vaccines are under development and one...

Drug Descriptors:

*
aluminum hydroxide; antigen; carrier protein; diphtheria toxin; diphtheria toxoid;
nerve cell adhesion molecule; oligosaccharide; outer membrane protein;
polysaccharide vaccine --drug therapy--dt; polysaccharide vaccine--pharmacology--pd;
tetanus toxoid

Medical Descriptors:

CAS Registry Number: ...80206-84-4 (aluminum hydroxide); 80700-39-6 (carrier protein); 57425-69-1...

SECTION HEADINGS:

9/3,k/8 (Item 3 from file: 72) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0080974369 EMBASE No: 2006034321

YdgG (TqSA) controls biofilm formation in Escherichia coli K-12 through autoinducer 2 transport

Herzberg M.; Kaye I.K.; Peti W.; Wood T.K.
Department of Chemical Engineering, University of Connecticut, 191 Auditorium
Road, Storrs, CT 06269-3222, United States
Author email: Thomas.Wood@chemail.tamu.edu
Corresp. Author/Affil: Wood T.K.: Department of Chemical Engineering, Texas A and M
University, 220 Jack E. Brown Building, College Station, TX 77843-3122, United
States
Corresp. Author Email: Thomas.Wood@chemail.tamu.edu

Journal of Bacteriology (J. Bacteriol.) (United States) January 1, 2006 ,
188/2 (587-598)

CODEN: JOBAA ISSN: 0021-9193

Item Identifier (DOI): 10.1128/JB.188.2.587-598.2006

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 72

...for type 1 fimbriae, autotransporter protein Ag43, curli production, colanic acid production, and production of polysaccharide adhesin. Eighty genes not previously related to biofilm formation were also identified, including those that encode...

Drug Descriptors:

* carrier protein--endogenous compound--ec; *gene product --endogenous compound--ec

polysaccharide.txt
acid; adhesin; biotin; crystal violet; membrane protein--endogenous compound--ec;
methionine; polysaccharide; polysialic acid; streptomycin; thiamine; unclassified
drug
Medical Descriptors:
CAS Registry Number: 58-85-5 (biotin); 80700-39-6 (carrier protein); 467-63-0...
SECTION HEADINGS:

9/3,K/9 (Item 4 from file: 72) Links
Fulltext available through: STIC Full Text Retrieval Options

EMBASE
(c) 2008 Elsevier B.V. All rights reserved.
0080146466 EMBASE No: 2004329105

Short-chain oligosaccharide protein conjugates as experimental pneumococcal
vaccines

Jansen W.T.M.; Snippe H.
Eijkman-Winkler Institute, Heidelberglaan 100, 3584CX Utrecht, Netherlands
Author email: W.T.M.Jansen@lab.azu.nl
Corresp. Author/Affil: Jansen W.T.M.: Eijkman-Winkler Institute, G04-614 UMC,
Department of Microbiology, Heidelberglaan 100, 3584 CX Utrecht, Netherlands
Corresp. Author Email: W.T.M.Jansen@lab.azu.nl

Indian Journal of Medical Research, Supplement (Indian J. Med. Res. Suppl.) (India)
August 13, 2004 , 119/MAY (7-12)
ISSN: 0367-9012

Document Type: Journal ; Short Survey Record Type: Abstract
Language: English Summary language: English
Number of References: 58

...vaccines. After a short overview of the development of pneumococcal vaccines
from the 23 - valent polysaccharide vaccines to polysaccharide-protein conjugate
vaccines, it focuses on the vaccine potential of synthetic oligosaccharides,
conjugated to carrier...
Drug Descriptors:

adhesin--drug development--dv; adhesin--drug therapy--dt; antibiotic agent--drug
therapy--dt; autolysin--drug development--dv; autolysin--drug therapy--dt; bacterial
polysaccharide--endogenous compound--ec; bacterial vaccine--drug development--dv;
bacterial vaccine --drug therapy--dt; carrier protein--clinical trial--ct; carrier
protein--drug combination--cb; carrier protein--drug development--dv; carrier
protein--drug therapy--dt; diphtheria toxoid--clinical trial--ct; diphtheria
toxoid--drug combination--cb; diphtheria toxoid... ..dv; outer membrane
protein--drug therapy--dt; pneumolysin--drug development--dv; pneumolysin--drug
therapy--dt; polysaccharide vaccine--clinical trial--ct; polysaccharide
vaccine--drug combination--cb; polysaccharide vaccine--drug development--dv;
polysaccharide vaccine--drug therapy--dt; synthetic peptide--drug combination--cb;
synthetic peptide--drug development--dv; synthetic...

Medical Descriptors:
CAS Registry Number: 97089-74-2 (autolysin); 80700-39-6 (carrier protein);
57425-69-1...
SECTION HEADINGS:

9/3,K/10 (Item 1 from file: 399) Links
CA SEARCH(R)
(c) 2008 American Chemical Society. All rights reserved.

141294673 CA: 141(18)294673p PATENT
Capsular polysaccharide-staphylococcal surface adhesin carrier protein conjugates as
vaccines for immunization against nosocomial infections
Inventor (Author): Pavliak, Viliam; Baker, Steven Morris; Pillai, Subramonia
Padmanaba

polysaccharide.txt

Location: USA

Assignee: Wyeth Holdings Corporation; Wyeth Corp.

Patent: PCT International ; WO 200480490 A2 Date: 20040923

Application: WO 2004US6661 (20040304) *US PV452728 (20030307)

Pages: 81 pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

Class: A61K-047/48A; C07K-016/12B; A61K-039/385B

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW
Designated Regional: BW; GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

9/3,K/11 (Item 1 from file: 135) Links

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000322939 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from the 84105 Israel, United States and United Kingdom report details of new studies and findings in the area of pneumococcal

Immunotherapy weekly, August 2, 2006, p.380

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count:

952

...TEXT: 84105 Israel, United States and United Kingdom.

Study 1: Pneumococcal 6-phosphogluconate-dehydrogenase, a putative adhesin, induces protective immune response in mice.

... noted researchers in Israel.

"This study assesses the role of 6PGD in pathogenesis as an adhesin and its ability to elicit a protective immune response in mice. Recombinant 6PGD (r6PGD) was...

...serotype 3 (strain WU2)," said D. Daniely and colleagues at Soroka University. "r6PGD interference in adhesion of three genetically unrelated unencapsulated pneumococcal strains (3.8, 14.8, and R6) and two ...

...with a lethal dose of ."

The investigators reported, "r6PGD inhibited 90% and 80% of pneumococcal adhesion to the A549 cells of three unencapsulated strains and two encapsulated strains, respectively, in a concentration-dependent manner ($p < 0.05$). Antibodies to r6PGD produced in mice significantly inhibited bacterial adhesion to A549 cell ($p < 0.05$). Immunization of mice with r6PGD protected 60% ($p < 0...$

...have identified 6PGD as a surface-located immunogenic lectin protein

polysaccharide.txt
capable of acting as an adhesin. 6PGD importance to bacterial
pathogenesis was demonstrated by the ability of r6PGD to elicit a...

...they concluded.

Dantiely and associates published their study in (Pneumococcal
6-phosphogluconate-dehydrogenase, a putative adhesin, induces
protective immune response in mice. Clin Exp Immunol, 2006;144(2):254-263).
For...

...84105 Israel. ymizr@bgumail.bgu.ac.il.

Study 2: Intranasal immunization with the cell wall
polysaccharide elicited antibody-independent,
interleukin-17A-mediated, cross-serotype immunity to pneumococci.

According to recent research...

...polysaccharides, which define the 90 known serotypes. Whether antibody
to the species-common cell wall polysaccharide (C-Ps) is protective
has been a matter of controversy. Here we show that C...

...17A-mediated, cross-serotype immunity to pneumococci in mice immunized
intranasally with the cell wall polysaccharide. Infect Immun,
2006;74(4):2187-2195).

For additional information, contact Richard Malley, Division of...

...States, "Pneumolysin, the pore-forming toxin produced by , may have an
application as an immunogenic carrier protein in future
pneumococcal conjugate vaccines. Most of the 90 serotypes identified
produce pneumolysin; therefore, this...

9/3,K/12 (Item 2 from file: 135) Links
NewsRx Weekly Reports
(C) 2008 NewsRx. All rights reserved.

0000310980 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Reports from the United States and United Kingdom describe recent advances
in pneumococcal research

Biotech Business Week, June 22, 2006, p.393

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1040

...TEXT: United Kingdom.

Study 1: Investigators have developed an opsonin inhibition assay for
evaluation of complex polysaccharide protective epitopes.

... published their study in Vaccine (Development of an opsonin
inhibition assay for evaluation of complex polysaccharide protective
epitopes. Vaccine, 2006;24(11):1941-1948).

For additional information, contact Tessie McNeely, Merck...

...the pore-forming toxin produced by Streptococcus pneumoniae , may have

polysaccharide.txt
an application as an immunogenic carrier protein in future
pneumococcal conjugate vaccines. Most of the 90 S. pneumoniae serotypes
identified produce pneumolysin...

...for antibodies to several pneumococcal proteins: choline binding protein
A (Cbpa), pneumolysin (Ply), pneumococcal surface adhesin A (PsaA),
and pneumococcal surface protein A (Pspa). Adenoidal mononuclear cells
(MNC) were cultured with...

9/3,K/13 (Item 1 from file: 357) Links

Derwent Biotech Res.

(c) 2008 Thomson Reuters. All rights reserved.

0355392 DBA Accession No.: 2005-01096 PATENT

New polysaccharide-protein conjugate comprising a capsular polysaccharide of
Neisseria meningitidis serogroup A, C, w-135 or Y, useful in preparing a vaccine for
immunizing a human patient against Neisseria meningitidis bacterium polysaccharide
and carrier protein conjugate for vaccine

Author: RYALL R P

Patent Assignee: AVENTIS PASTEUR INC 2004

Patent Number: WO 2004103400 Patent Date: 20041202 WPI Accession No.: 2004-834172
(200482)

Priority Application Number: US 468581 Application Date: 20030507

National Application Number: WO 2004US14466 Application Date: 20040507

Language: English

New polysaccharide-protein conjugate comprising a capsular polysaccharide of
Neisseria meningitidis serogroup A, C, w-135 or Y, useful in preparing a vaccine for
immunizing a human patient against Neisseria meningitidis bacterium polysaccharide
and carrier protein conjugate for vaccine

Abstract: DERWENT ABSTRACT: NOVELTY - A new polysaccharide-protein conjugate
comprises a capsular polysaccharide of Neisseria meningitidis serogroup A, C, w-135
or Y, conjugated to one or more carrier proteins, where the composition comprises
0.5 to 15 microgram/ml of each capsular polysaccharide to an average size of less
than 100000 daltons. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for
the following: (1) a composition comprising the polysaccharide-protein conjugate;
(2) a method of inducing an immunological response against meningococcal A, Y or...
...3) a method of immunizing a human patient against Neisseria meningitidis.

BIOTECHNOLOGY - Preferred Conjugate: The polysaccharide-protein conjugate comprises
a capsular polysaccharide of Neisseria meningitidis serogroup A, C, w-135 or Y,
conjugated to one or more carrier proteins, where the composition comprises 0.5 to
15 mug/ml of each capsular polysaccharide to an average size of less than 100000, or
5000-75000, 7000-50000, 8000-35000, 12000-25000 or 15000-22000 daltons. The average
ratio of derivatized polysaccharide to carrier protein is about 1:1-1:20, 1:2-1:10,
1:2-1:6, 1:... ..or minus 0.5) or 1:(4 plus or minus 0.25) (w/w). The carrier
protein comprises a bacterial toxin or toxoid, or a bacterial outer membrane
protein. The carrier protein comprises a diphtheria toxin, diphtheria toxoid,
CRM197, tetanus toxoid, pertussis toxoid, E. coli LT, E... ..membrane complex c
(OMPC), porin, transferrin binding protein, pneumolysin, pneumococcal surface
protein A (Pspa), pneumococcal adhesin protein (PsaA), ovalbumin, keyhole limpet
hemocyanin (KLH), bovine serum albumin (BSA) or purified protein derivative of
tuberculin (PPD). The carrier protein comprises a diphtheria toxin, diphtheria
toxoid, CRM97, tetanus toxoid, exotoxin A or outer membrane complex c (OMPC). The
capsular polysaccharide is derivatized to average size of 8000 to 35000 daltons. The
average ratio of derivatized polysaccharide to carrier protein is about 1:2-1:10 or
1:(4 plus or minus 1) (w/w)... ..an adjuvant comprising aluminum hydroxide, aluminum
phosphate, sodium phosphate and/or sodium chloride. The capsular polysaccharide is A
and w-135, Y and w-135, C and Y, C and w... ..in a human patient comprises
administering to the human patient a vaccine composition comprising the
polysaccharide-protein conjugate. The vaccine composition does not comprise an

polysaccharide.txt

adjuvant. Immunizing a human patient against *Neisseria meningitidis* comprises administering a vaccine composition comprising the polysaccharide-protein conjugate, whereby the human patient has a fourfold or greater increase in serum GMT...

...SBA-BR titer. ACTIVITY - Antibacterial. No biological data given. MECHANISM OF ACTION - vaccine. USE - The polysaccharide-protein conjugate is useful in preparing a vaccine composition for immunizing a human patient against...

E.C. Numbers:

Descriptors: *Neisseria meningitidis* capsular polysaccharide, diphtheria toxin, diphtheria toxoid, tetanus toxoid, pertussis toxoid, *Escherichia coli* LT, *Escherichia coli* ST, exotoxin-A, outer membrane complex-C, porin, transferrin binding protein, pneumolysin, pneumococcal surface protein-A, pneumococcal adhesin protein, ovalbumin, keyhole limpet hemocyanin, cattle serum albumin, purified tuberculin protein derivative carrier protein conjugate, immunization in human patient, appl. vaccine, *Neisseria meningitidis* infection therapy, prevention bacterium animal mammal...

9/3,K/14 (Item 2 from file: 357) Links

Derwent Biotech Res.

(c) 2008 Thomson Reuters. All rights reserved.

0342932 DBA Accession No.: 2004-15224 PATENT

Generating a *Staphylococcus* that overproduces a polysaccharide useful as a vaccine against staphylococcal infection comprises introducing into a bacterium an intercellular adhesion (ica) nucleic acid linked to an ica regulatory nucleic acid polysaccharide production via plasmid expression in host cell for in vaccine

Author: PIER G B; JEFFERSON K

Patent Assignee: BRIGHAM and WOMENS HOSPITAL INC 2004

Patent Number: WO 200443407 Patent Date: 20040527 WPI Accession No.: 2004-411631 (200438)

Priority Application Number: US 425569 Application Date: 20021112

National Application Number: WO 2003US36371 Application Date: 20031112

Language: English

Generating a *Staphylococcus* that overproduces a polysaccharide useful as a vaccine against staphylococcal infection comprises introducing into a bacterium an intercellular adhesion (ica) nucleic acid linked to an ica regulatory nucleic acid polysaccharide production via plasmid expression in host cell for in vaccine

Abstract: DERWENT ABSTRACT: NOVELTY - Generating (M1) a (*Staphylococcus*) bacterium that overproduces polysaccharide by introducing into a bacterium an intercellular adhesion (ica) nucleic acid operably linked to an ica regulatory nucleic acid, is new. DETAILED DESCRIPTION - Generating (M1) a (*Staphylococcus*) bacterium that overproduces polysaccharide comprises: (a) introducing into a bacterium, an intercellular adhesion (ica) nucleic acid operably linked to an ica regulatory nucleic acid (II), where the (II)... between and including nucleotides 9 and 43 of (S1), and that enhance production of a polysaccharide from an ica locus, and their complements, (b) introducing into a bacterium an ica nucleic acid operably linked to (II), where (II) comprises a mutant icaR nucleic acid, and measuring polysaccharide production from the bacterium, where a high level of polysaccharide production is indicative of (I) (c) recombinantly down-regulating wild-type icaR protein production, and... ica promoter region. INDEPENDENT CLAIMS are also included for: (1) a recombinant bacterium which overproduces polysaccharide and comprises an ica nucleic acid operably linked (II), where the bacterium is not MN8... MN8m), or a mutant icaR nucleic acid; (2) producing (M2) an antibody to a bacterial polysaccharide, by isolating a bacterial polysaccharide from (I), administering the isolated bacterial polysaccharide to a subject to produce an antibody, and harvesting antibody from the subject; (3) an... and its complements, where the fragment spans a MN8m mutation and enhances production of a polysaccharide from an ica locus when operably linked to an ica nucleic acid; (4) an expression... indicative of an isolated binding agent; (7) identifying (M4) an ica promoter sequence associated with polysaccharide overproduction, involves detecting a nucleic acid molecule having a sequence alteration from wild-type in... and 43 of (S1); (8) identifying (M5) an ica regulatory nucleic acid molecule that enhances polysaccharide production, by altering a nucleic acid molecule having (S1), and

polysaccharide.txt

determining a level of reporter....higher than wild-type level of reporter protein production is indicative of (II) that enhances polysaccharide production; (9) a composition (C1) comprising an isolated binding agent that binds to a nucleic....disclosed. BIOTECHNOLOGY - Preferred Method: The steps (a), (c) and (d) of (M1), further involve measuring polysaccharide production from the bacterium, where a high level of polysaccharide production is indicative of (I). (II) comprises a fully defined sequence of 55 base pairs ...IcaR protein that binds to a target less efficiently than wild-type IcaR protein. The polysaccharide is poly-N-acetyl glucosamine (PNAG). In (C) of (M1), the wild-type IcaR protein...nucleic acid molecule with the candidate molecule to determine if the candidate molecule is a polysaccharide molecule is a polysaccharide synthesis modulator, where the candidate molecule is a polysaccharide synthesis modulator if expression from the reporter construct is altered. The candidate molecule is a...nucleic acid molecule, is indicative of the presence of an ica promoter sequence associated with polysaccharide over-production. The nucleic acid molecule is detected by contacting a candidate nucleic acid with...In (M5), the reporter nucleic acid is an ica nucleic acid and reporter production is polysaccharide production. The nucleic acid molecule is altered recombinantly, or altered naturally during bacterial culture. (M6)...protein G, a mammalian protein, viral protein, fungal protein, parasite protein, fibrinogen-binding protein, vaccine carrier protein, or IcaA, IcaD, IcaB or IcaC. Preferred Bacterium: In the recombinant polysaccharide over-producing bacterium, the mutant icaR nucleic acid is a deletion of wild-type icaR...ACTION - Vaccine; Anti-poly-N-acetyl glucosamine antibodies. USE - (M1) is useful for generating a polysaccharide over-producing bacterium, such as Staphylococcus, which is chosen from S. epidermidis, S. aureus, S....S. pasteuri and S. piscifermentans, where the recombinant bacterium is useful for producing a bacterial polysaccharide, which involves culturing the bacterium in a growth medium, and harvesting the bacterial polysaccharide from the culture. The bacterial polysaccharide is composed of beta 1-6 linked glucosamine units, where 0-100% of the units are acetate substituted, or less than 50% of the units are acetate substituted, and the polysaccharide is useful in producing antibody in a non-human subject such as rabbit or mouse. The method further involves formulating the bacterial polysaccharide as a vaccine (claimed). The polysaccharide produced using (I), is useful for immunizing humans and animals against infection by Staphylococcus bacteria...or infected with infectious agents. ADVANTAGE - (M1) enables generation of bacterium capable of over-producing polysaccharide such as poly-N-acetyl glucosamine (claimed). EXAMPLE - Expression plasmid pCART-NT was used to...histidine residues and an Xpress epitope to the amino-terminus of the protein. The intercellular adhesion (Ica) R Tcar proteins and the vector expression control were sequentially purified. The lac operon... E.C. Numbers: Descriptors: polysaccharide prep., vector plasmid pCART-NT-mediated gene transfer expression in Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus...caprae, Staphylococcus hemolyticus, Staphylococcus auricularis, Staphylococcus intermedius, Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus piscifermentans, mutant intercellular adhesion DNA, appl. bacterium infection recombinant vaccine, diagnosis, therapy strain improvement protein DNA sequence protein sequence...

9/3,K/15 (Item 1 from file: 149) Links
TGG Health&Wellness DB(SM)
(c) 2008 Gale/Cengage. All rights reserved.
01057468 Supplier Number: 02665462 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Gordon Research Conferences. (includes schedules) (calendar)

Science , v219 , p1095(35)
March 4 ,
1983

Document Type: calendar Publication Format: Magazine/Journal
ISSN: 0036-8075
Language: English
Record Type: Fulltext Target Audience: Academic
Page 22

...occupancy) \$230.00

Nonresident conferee (meals, no room) \$190.00

Guest (room, meals) \$170.00

Adhesion

New Hampton School

Robert A. Draughn, chairperson; David W. Dwight, vice chairperson.

22 August. F...

...Hightemperature polymers for aerospace applications'; R. Young,

"Ligno-cellulosic adhesives"; N. S. Eiss, "Role of adhesion in friction and wear of polymers." Poster session.

24 August. G. P. Anderson, "Analyses of standard adhesion test specimens"; W. S. Johnson, "Cyclic debonding of adhesively bonded composites"; R. S. Williams, "Characterization...Beachey, "Bacterial

invasiveness--introduction"; G. Hazelbauer, "Bacterial chemotaxis"; I.

Ofek, "Molecule of recognition mediating bacterial adhesion"; F.

Audibert, "Synthetic analogs of bacterial cell walls (muramyl dipetides) as adjuvants for synthetic vaccines...

...xanthus'; L. Shapiro, "Role of membrane biogenesis in the Caulobacter

cell cycle"; M. Bayer, "Membrane adhesion site." Porins (J.

Rosenbusch, session chairperson): J. Rosenbusch, "Structural aspects of

porins"; H. Nikaïdo, "Properties...immunoglobulins."

28 June. (P. A. Sandford, discussion leader): D. A. Brant, "Realistic molecular modeling of polysaccharide solution conformation"; G. O.

Aspinall, "Selective fragmentations of polysaccharides." (D. H. Ball,

discussion leader): K...Bart Chernow, "Catecholamine applications to

medicine's newest subspecialty: critical care medicine."

Cell Contact and Adhesion

Procter Academy

Jean Paul Revel, chairperson.

27 June. P. Armstrong, "Cell-cell adhesion"; G. Edelman,

"Cell-cell adhesion"; M. Kuehlenschmidt, D. Cox, L. Park and S.

Roseman, "Cell-cell adhesion"; M. Bernfield, "Cell-substrate

adhesion"; M. Bronner-Fraser, "Cell-substrate adhesion"; J.

Jamieson, "Cell-substrate adhesion."

28 June. E. D. Hay, "Cell-matrix interaction"; H. Kleinman,

"Cell-matrix interaction"; D. McClay...Elias, "Proteolipids and the

barrier." (Submitted posters, W. L. Epstein.)

10 August. Cell attachment and adhesion (M. Karasek, moderator): D. Gospodarowicz, "Attachment factors"; L. Liotta, "Laminin receptor"; L. Diaz, "Autoantibody probes..."

...K. Fukuyama, moderator): D. Rifkin, "Skin proteinase inhibitors"; Y.

Ishibashi, "In vitro changes in cell adhesion"; G. Lazarus,

"Regulation of serine proteinases"; D. Perez, "Skin cysteine proteinase and inflammation."

11 August...endothelial cells'; L. Curtiss, "Lipoprotein: Platelet interactions"; C. Bianco, "The fibronectin receptor."

23 June. Cellular adhesion mechanisms (M. Ginsberg, session

chairperson): T. Peterson, "Primary structure of fibronectin"; J. Lawler,

"Structurefunction relationships..."

...platelet: vessel wall interaction'; D. Meyer, "Is only a single vwf locus required for platelet adhesion?"

Heterocyclic Chemistry

New Hampton School

Albert Padwa, chairperson; William Moberg, vice chairperson.

11-15 July...into model bilayers; Robert Fillingame, "Proton translocating ATPase of Escherichia coli"; Ronald Kaback, "The lac

polysaccharide.txt
 carrier protein: From membrane to molecule'; H. Gobind
 Khorana, "Light transducing retinal-based pigments."
 21 June. Molecular...membrane lipids and proteins in cellular
 development: Ronald Schnaar, "Immobilized glycolipids support
 carbohydrate-specific cell adhesion"; William Lennarz, "Glycoprotein
 synthesis and embryonic development"; Lucy Shapiro, "Role of membrane
 biosynthesis in Caulobacter...Crystal, chairperson; Bjorn R. Olsen,
 co-chairperson.
 4 July. Structure of extracellular matrix components (collagens,
 adhesion proteins, proteoglycans) I (Bjorn R. Olsen, session
 chairperson): Klaus Kuhn, "Interstitial collagens"; Rupert Timp1, "Basement
 ...

9/3,K/16 (Item 1 from file: 444) Links
 New England Journal of Med.
 (c) 2008 Mass. Med. Soc. All rights reserved.
 00121353
 Copyright 2001 by the Massachusetts Medical Society

Medical Progress: Meningococcal Disease (Review Article)

Rosenstein, Nancy E.; Perkins, Bradley A.; Stephens, David S.; Popovic, Tanja;
 Hughes, James M.
 The New England Journal of Medicine
 May 3, 2001; 344 (18), pp 1378-1388
 Line count: 00583 Word Count: 08046

Text:

...Since the new meningococcal conjugate vaccines, like the currently available
 quadrivalent polysaccharide vaccine, will provide serogroup-specific protection, the
 distribution of serogroups is a key factor in...serogroups, most cases of
 meningococcal disease are caused by serogroups A and C, for which polysaccharide
 vaccines are effective, and serogroup B, which has a polysaccharide capsule that is
 poorly immunogenic in humans. The capsular polysaccharide is either a homopolymer or
 a heteropolymer consisting of monosaccharide, disaccharide, or trisaccharide
 repeating units...structures) that contain 50 percent lipooligosaccharide and 50
 percent outer-membrane proteins, phospholipids, and capsular polysaccharide. The
 endotoxin and probably other components stimulate cytokine production and the
 alternative complement pathway. N...meningitis. (Ref. 66) Nonculture methods, such
 as the use of commercially available kits to detect polysaccharide antigen in
 cerebrospinal fluid, have been used to enhance the laboratory diagnosis. These
 methods are...Ref. 80-82)*Table 3.-Schedule for Administering Chemoprophylaxis
 against Meningococcal Disease *.*TABLE OMITTED**
 Meningococcal Polysaccharide Vaccine

The quadrivalent polysaccharide vaccine that provides protection against serogroups
 A, C, Y, and W-135 is the only...Routine childhood vaccination with the
 quadrivalent meningococcal polysaccharide vaccine is not recommended because of its
 relative ineffectiveness in young children, who have the...informed decisions
 about vaccination.

Improved Vaccines

Unlike serogroup A and C polysaccharides, the serogroup B polysaccharide has a
 capsule ((alpha)2-8]-linked polysialic acid) that is identical in structure to...
 ...To improve the immunogenicity of the serogroup B polysaccharide, researchers have
 covalently linked it to carrier proteins and adsorbed it to aluminum; this vaccine
 has induced a serogroup-specific response in animals. (Ref. 96) Use of serogroup B
 polysaccharide vaccines in humans has been limited because of the theoretical risk
 that these vaccines will...serogroup A and C polysaccharides has been the use of
 peptides that mimic the capsular polysaccharide in complex with or conjugated to
 potent carrier-protein molecules in order to elicit a T-cell-dependent response.

polysaccharide.txt

(Ref. 103) In addition, the...a reasonable public health strategy for controlling meningococcal disease, but the shortcomings of the quadrivalent polysaccharide vaccine limit its usefulness. New serogroup B vaccines, now being developed, are unlikely to be...

Cited References

- ...FP, Cole R, Dankert J, Frosch M, van Putten JP. Neisseria meningitidis producing the Opc adhesin binds epithelial cell proteoglycan receptors. Mol Microbiol 1998;27:1203-12.
33. Virji M, Evans...against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1998;114:362-9.
44. Figueroa JE, Densen P. Infectious diseases...J, Randolph M, Samuelson JS, Hankins WA. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis 1986;154:1033-6.
84. Scheifele DW, Bjornson G... ..RA, Bactos CO, et al. Assessment of the protection conferred by anti-group C meningococcal polysaccharide vaccine to 6 to 36 month-old children. Rev Inst Adolfo Lutz 1978;38:77... ..Draper TF, Gotshlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infantsAW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985;2:114-8.
92. Zangwill KM, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994;169:847-52.
93. Granoff... ..Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998;178:870-4.
94. MacLennan J, Obaro S, Deeks J... ..Srivastava N, Smithson SL, et al. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine 2000;18:1253-63... ..S, Leach A, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995;171:632-8.
107. Leach... ..in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997;175:200-4.
108. Ramsay ME, Andrews N...

?